Share This Author
Phenotype of Barrett's Esophagus and Intestinal Metaplasia of the Distal Esophagus and Gastroesophageal Junction: An Immunohistochemical Study of Cytokeratins 7 and 20, Das-1 and 45MI
The immunophenotypic features of SSBE and IMGEJ are similar and closely resemble those seen in classic LSBE, but are distinct from IMGA.
Relationship of Extraintestinal Involvements in Inflammatory Bowel Disease (New Insights into Autoimmune Pathogenesis)
- K. Das
- Medicine, BiologyDigestive Diseases and Sciences
The identified pathogeneticautoimmune mechanisms include genetic susceptibility, cytokine imbalances, antigenic display of autoantigen, aberrant self-recognition, andmunopathogenetic autoantibodies against organ-specificcellular antigen(s) shared by colon and extracolonicorgans.
Intestinal Differentiation in Metaplastic, Nongoblet Columnar Epithelium in the Esophagus
Evidence is provided that metaplastic esophageal columnar epithelium without goblet cells shows phenotypic evidence of intestinal differentiation and supports the theory that squamous epithelia converts initially to nongoblet columnar exemplars before gobleT cell metaplasia.
Helicobacter pylori associated chronic gastritis, clinical syndromes, precancerous lesions, and pathogenesis of gastric cancer development.
Patients with precancerous lesions (molecular alterations) that do not reverse after H. pylori treatment, represent the "point of no return" and may be at high risk for the development of GC, therefore, earlier H.pylori eradication should be considered for preventing GC development prior to the appearance of precancersous lesions.
Non‐response to infliximab may be due to innate neutralizing anti‐tumour necrosis factor‐α antibodies
- E. Ebert, K. Das, V. Mehta, C. Rezac
- Biology, MedicineClinical and experimental immunology
- 1 December 2008
Any TNF‐ α‐mediated disease process would be neutralized by intrinsic antibodies, so that the disease is likely to be driven by non‐TNF‐α‐mediated events.
The metabolism of salicylazosulphapyridine in ulcerative colitis
Serum total SP concentration of 20 to 50 μg/ml appeared to coincide with clinical improvement in the absence of any side effects related to salicylazosulphapyridine, and no such relationship could be shown with serum SASP, individual metabolites, or 5-aminosalicyclic acid.
Barrett's esophagus: cancer and molecular biology
- M. Gibson, Arashinder S. Dhaliwal, M. Bajpai
- MedicineAnnals of the New York Academy of Sciences
- 1 October 2013
The following paper on the molecular biology of Barrett's esophagus (BE) includes commentaries on signaling pathways central to the development of BE including Hh, NF‐κB, and IL‐6/STAT3; surgical…
Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype.
- K. Das, M. Eastwood, J. McManus, W. Sircus
- Medicine, ChemistryThe New England journal of medicine
- 6 September 1973
Reintroduction of a therapeutic dose of salicylazosulfapyridine was achieved by an initially small dose, which was then gradually increased, and this method could be continued in 26 out of 28 patients who exhibited side effects.
Clinical Pharmacokinetics of Sulphasalazine
In long-term therapy of ulcerative colitis doses of 2 to 3g/day of sulphasalazine are most likely to sustain remissions and avoid toxicity, and a positive correlation exists between serum total sulphapyridine concentration and both therapeutic efficacy and toxicity.